Document is current
Any future updates will be listed below
-
Authors
Alyaydin, Emyal
Gotschy, Alexander
Parianos, Danaë
Nägele, Matthias P.
Tudorache, Igor
Flammer, Andreas J.
Stehli, Julia
-
Funding
Funding for this research was provided by:
University of Zurich
- License Information
-
More Information
Article History
Accepted: 2 February 2025
First Online: 13 February 2025
Declarations
:
: E. A. reports educational and training grant from the European Society of Cardiology (ESC), congress grants from the Heart Failure Association of the ESC, congress grants from the German Society of Cardiology and German Society of Internal Medicine, all unrelated to this article. M.P.N. reports speaker fees by AstraZeneca and Vifor Pharma unrelated to the article, consultancy fees by Boehringer Ingelheim and Pierre Fabre, and congress travel support by Pfizer, all unrelated to the article. I. T. was a medical consultant for corlife oHG and was involved in approval of homografts. A.J.F. reports fees from Alnylam, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Fresenius, Medtronic, MSD, Mundipharma, Novartis, NovoNordisk, Pierre Fabre, Pfizer, Roche, Vifor, and Zoll, as well as grant support by Novartis, AstraZeneca and Berlin Heart unrelated to this article. All other authors declare no conflict of interest.
